Market Overview: Colorectal Cancer   26-page PDF document
$299.00

Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Log in to unlock full preview.
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Market Overview: Colorectal Cancer (26-page PDF document) Preview Image
Arrow   Click main image to view in full screen.

Market Overview: Colorectal Cancer (PDF)

PDF document 26 Pages

$299.00

Add to Cart
  


Immediate download
Editable with PDF editor
Free lifetime updates

BENEFITS OF THIS PDF DOCUMENT

  1. Colorectal cancer therapy market will grow modestly from $8.4 billion in 2015 to $12.5 billion in 2025
  2. Etiology and Pathophysiology
  3. Market Overview

HEALTHCARE PDF DESCRIPTION

This product (Market Overview: Colorectal Cancer) is a 26-page PDF document, which you can download immediately upon purchase.

The colorectal cancer therapy market will grow modestly from $8.4 billion in 2015 to $12.5 billion in 2025 in the seven major pharmaceutical markets under study. Growth will be fueled by continued uptake of premium-priced therapies and the approval of six emerging therapies. In 2025, immune checkpoint inhibitors will hold an impressive 33% share of this market.

Two immune checkpoint inhibitors are expected to launch for colorectal cancer (Merck & Co.'s Keytruda [pembrolizumab] and Roche/Genentech/Chugai's Tecentriq [atezolizumab]), significantly contributing to the aforementioned market growth. Their combined major-market sales will total approximately $4.2 billion in 2025, driven largely by the two agents: approval in MSI-H and dMMR patient populations.

Introduction
Key Findings
Market Share of Cancer Drug Classes in 2015 and 2025
Market SWOT Analysis
Etiology and Pathophysiology
Key Findings
Expert Insight
Pathophysiology
Anatomy
Subtypes
Staging and Classification
Key Pathways and Drug Targets
Market Outlook
Key Findings
Expert Insight
Market Overview
Market Drivers and Constraints
What Factors Are Driving the Market?
What Factors Are Constraining the Market?

Got a question about the product? Email us at support@flevy.com or ask the author directly by using the "Ask the Author a Question" form. If you cannot view the preview above this document description, go here to view the large preview instead.

Source: Best Practices in Healthcare, Cancer PDF: Market Overview: Colorectal Cancer PDF (PDF) Document, pharmzolgas


$299.00

Add to Cart
  

ABOUT THE AUTHOR

Author: pharmzolgas
Additional documents from author: 3

Ask the Author a Question

You must be logged in to contact the author.

Click here to log in Click here register

Did you know?
The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.




Trusted by over 10,000+ Client Organizations
Since 2012, we have provided best practices to over 10,000 businesses and organizations of all sizes, from startups and small businesses to the Fortune 100, in over 130 countries.
AT&T GE Cisco Intel IBM Coke Dell Toyota HP Nike Samsung Microsoft Astrazeneca JP Morgan KPMG Walgreens Walmart 3M Kaiser Oracle SAP Google E&Y Volvo Bosch Merck Fedex Shell Amgen Eli Lilly Roche AIG Abbott Amazon PwC T-Mobile Broadcom Bayer Pearson Titleist ConEd Pfizer NTT Data Schwab




Read Customer Testimonials

 
"As a consulting firm, we had been creating subject matter training materials for our people and found the excellent materials on Flevy, which saved us 100's of hours of re-creating what already exists on the Flevy materials we purchased."

– Michael Evans, Managing Director at Newport LLC
 
"I am extremely grateful for the proactiveness and eagerness to help and I would gladly recommend the Flevy team if you are looking for data and toolkits to help you work through business solutions."

– Trevor Booth, Partner, Fast Forward Consulting
 
"As a small business owner, the resource material available from FlevyPro has proven to be invaluable. The ability to search for material on demand based our project events and client requirements was great for me and proved very beneficial to my clients. Importantly, being able to easily edit and tailor "

– Michael Duff, Managing Director at Change Strategy (UK)
 
"As a young consulting firm, requests for input from clients vary and it's sometimes impossible to provide expert solutions across a broad spectrum of requirements. That was before I discovered Flevy.com.

Through subscription to this invaluable site of a plethora of topics that are key and crucial to consulting, I "

– Nishi Singh, Strategist and MD at NSP Consultants
 
"I like your product. I'm frequently designing PowerPoint presentations for my company and your product has given me so many great ideas on the use of charts, layouts, tools, and frameworks. I really think the templates are a valuable asset to the job."

– Roberto Fuentes Martinez, Senior Executive Director at Technology Transformation Advisory
 
"[Flevy] produces some great work that has been/continues to be of immense help not only to myself, but as I seek to provide professional services to my clients, it gives me a large "tool box" of resources that are critical to provide them with the quality of service and outcomes they are expecting."

– Royston Knowles, Executive with 50+ Years of Board Level Experience
 
"As an Independent Management Consultant, I find Flevy to add great value as a source of best practices, templates and information on new trends. Flevy has matured and the quality and quantity of the library is excellent. Lastly the price charged is reasonable, creating a win-win value for "

– Jim Schoen, Principal at FRC Group
 
"Flevy is now a part of my business routine. I visit Flevy at least 3 times each month.

Flevy has become my preferred learning source, because what it provides is practical, current, and useful in this era where the business world is being rewritten.

In today's environment where there are so "

– Omar HernĂ¡n Montes Parra, CEO at Quantum SFE


Your Recently Viewed Documents


Customers Also Like These Documents

Related Management Topics


Healthcare Cancer Value Chain Analysis Integrated Financial Model

Download our FREE Strategy & Transformation Framework Templates

Download our free compilation of 50+ Strategy & Transformation slides and templates. Frameworks include McKinsey 7-S Strategy Model, Balanced Scorecard, Disruptive Innovation, BCG Experience Curve, and many more.